immunotherapy

The International Agency for Research on Cancer (IARC) forecasts a 58 per cent surge in GI cancer cases by 2040 globally 

KEYTRUDA is now approved for 14 indications across eight tumour types in India

The technology enables the screening of substantial amounts of cancer samples without requiring fresh biopsies or biological…

Imfinzi is the only immunotherapy-based combination treatment option in India that offers significantly improved survival rates in…

In a clinical trial of 42 women with metastatic breast cancer, 28 (or 67 per cent) generated an immune reaction against their…

The four molecules expected to launch first, autogene cevumeran, GRANITE-001, ATL001, and Genocea Biosciences’ GEN-009 have…

Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined…

The designation will provide Glycostem with eligibility for seven years of market exclusivity and clear FDA guidance on specific…

Adds phase 1 isoform-selective TGF-beta inhibitor AVID200 to pipeline

Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop…